A. M. Inkin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
A. M. Inkin has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra S. Badyan
Rostov State Medical University
1 shared publication - Eleonora V. Dudnikova
Rostov State Medical University
1 shared publication - Svetlana G. Piskunova
Rostov State Medical University
1 shared publication - V. N. Kovalenko
Rostov State Medical University
1 shared publication
Latest Publications
- Open Access
- 28 June 2023
- Published by Rostov State Medical University in Medical Herald of the South of Russia
- Vol. 14 (2) , 76-83
Multisystem inflammatory syndrome (MIS) or Kawasaki-like syndrome associated with COVID-19
With the emergence of the SARS-CoV-2 virus in December 2019, all countries around the world have implemented various strategies to prevent its spread and intensively search for effective treatments. Initially, severe cases of the disease were considered only in adults, but later information appeared on the severe course of the disease in children and adolescents. This condition, which occurs as part of the transferred COVID-19, is called multisystem inflammatory syndrome (MIS) or Kawasaki-like syndrome. The available data indicate that MVS is the result of an innate and adaptive immune response characterized by a cytokine storm and a delayed immunological response to SARS-CoV-2. Epidemiological, clinical, and immunological differences classify MVS as a distinct syndrome from Kawasaki disease (БК), including age range, and geographic and ethnic distribution of patients. It should be noted that new data from patients with MVS point to unique characteristics of the immunological response, as well as clinical similarities with other inflammatory syndromes, which can serve as a guide in the search for molecular mechanisms involved in MVS. This review presents an analysis of studies on this topic: features of pathogenesis, diagnosis, treatment methods, as well as further directions for studying the problem. The search for mechanisms for the development of MVS in children continues, and, in turn, medical alertness, timely diagnosis and treatment make it possible to achieve the best possible result for such patients.
- 28 June 2023
- Published by Rostov State Medical University in Medical Herald of the South of Russia
- Vol. 14 (2) , 76-83
Open AccessMultisystem inflammatory syndrome (MIS) or Kawasaki-like syndrome associated with COVID-19
With the emergence of the SARS-CoV-2 virus in December 2019, all countries around the world have implemented various strategies to prevent its spread and intensively search for effective treatments. Initially, severe cases of the disease were considered only in adults, but later information appeared on the severe course of the disease in children and adolescents. This condition, which occurs as part of the transferred COVID-19, is called multisystem inflammatory syndrome (MIS) or Kawasaki-like syndrome. The available data indicate that MVS is the result of an innate and adaptive immune response characterized by a cytokine storm and a delayed immunological response to SARS-CoV-2. Epidemiological, clinical, and immunological differences classify MVS as a distinct syndrome from Kawasaki disease (БК), including age range, and geographic and ethnic distribution of patients. It should be noted that new data from patients with MVS point to unique characteristics of the immunological response, as well as clinical similarities with other inflammatory syndromes, which can serve as a guide in the search for molecular mechanisms involved in MVS. This review presents an analysis of studies on this topic: features of pathogenesis, diagnosis, treatment methods, as well as further directions for studying the problem. The search for mechanisms for the development of MVS in children continues, and, in turn, medical alertness, timely diagnosis and treatment make it possible to achieve the best possible result for such patients.